Anticancer Res. 全文

1: Anticancer Res. 2008 Jan-Feb;28(1A):37-43.Links
Induction of necrosis in human myeloma cells by kigamicin.Nakamura M, Esumi H, Jin L, Mitsuya H, Hata H.
Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.

BACKGROUND: Kigamicin (KGM) is a novel compound derived from Actinomycetes that was originally reported to induce necrosis in pancreatic cancer cells only under nutrient-starved conditions via inhibition of PI3-kinase. The effects of KGM on myeloma cells were investigated. MATERIALS AND METHODS: Cytotoxic activity was quantified using WST8 assay. Necrosis was determined by Annexin V/PI staining. Regulatory protein levels were assessed by Western blot. LY294002 was utilized as a PI3-kinase inhibitor. RESULTS: KGM induced necrosis in myeloma cells in nutrient rich conditions with a CC50 of approximately 100 nM. KGM did not induce necrosis in normal lymphocytes. Cyclin D1, p21, p-AKT and p-ERK were inhibited by KGM while LY294002 did not in